Overview

VK4-116 Phase I Study With Food-Effect

Status:
NOT_YET_RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.

Phase:

PHASE1

Details

Lead Sponsor:

National Institute on Drug Abuse (NIDA)

Collaborator:

Altasciences Company Inc.

Treatments:

VK4-116